
Join to view full profile
460 W 10th AveColumbus, OH 43210
Phone+1 614-293-6529
Fax+1 614-293-9469
Dr. Monk is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1999 - 2002
OhioHealth/Riverside Methodist HospitalResidency, Internal Medicine, 1996 - 1999
Ohio State University College of MedicineClass of 1996
Certifications & Licensure
OH State Medical License 1999 - 2028
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma Start of enrollment: 2006 Nov 08
- Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2009 Oct 29
Publications & Presentations
PubMed
- Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neur...Rahul Aggarwal, Jingsong Zhang, Paul Monk, Xinhua Zhu, Rob Jones
Journal for Immunotherapy of Cancer. 2026-05-11 - 16 citationsNCCN Guidelines® Insights: Testicular Cancer, Version 2.2025.Timothy Gilligan, Daniel W Lin, Nabil Adra, Aditya Bagrodia, Darren R Feldman
Journal of the National Comprehensive Cancer Network. 2025-04-01 - 2 citationsTyrosine Kinase Inhibitors Outperform Immune Checkpoint Inhibitors in Bone-Predominant Metastatic Renal Cell Carcinoma: A Multicenter Real-World Analysis.Lingbin Meng, Sarah P Psutka, Jinesh Gheeya, Mingjia Li, Meghana Noonavath
Journal of Cancer. 2025-01-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









